50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
World Bank head says he's not a climate denier, won't quit
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
World Bank head says he's not a climate denier, won't quit
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
World Bank head says he's not a climate denier, won't quit
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
MarketBeat: Week in Review 9/19 – 9/23
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
China using civilian ships to enhance navy capability, reach
German leader seeks energy deals, alliances on Gulf trip
Goldman Sachs Alum Sounds Alarm on "Next US Crisis" (Ad)
World Bank head says he's not a climate denier, won't quit
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:STOK

Stoke Therapeutics - STOK Stock Forecast, Price & News

$13.03
-1.87 (-12.55%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.00
$14.98
50-Day Range
$13.03
$22.53
52-Week Range
$9.55
$33.06
Volume
325,627 shs
Average Volume
242,349 shs
Market Capitalization
$513.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.83

Stoke Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
244.1% Upside
$44.83 Price Target
Short Interest
Bearish
27.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.69) to ($2.96) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

973rd out of 1,080 stocks

Pharmaceutical Preparations Industry

474th out of 535 stocks

STOK stock logo

About Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

Stoke Therapeutics (NASDAQ:STOK) Sees Large Volume Increase
Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study
Stoke Therapeutics Posts Wider Loss In Q2
Stoke Therapeutics, Inc. (STOK)
Coming out was a necessary step
ADPT, SGMO and RDBX among after hour movers
Recap: Stoke Therapeutics Q4 Earnings
See More Headlines
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Company Calendar

Last Earnings
8/08/2022
Today
9/24/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.83
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+244.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-85,810,000.00
Pretax Margin
-1,546.24%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.92 per share

Miscellaneous

Free Float
34,413,000
Market Cap
$513.64 million
Optionable
Not Optionable
Beta
0.56

Key Executives

  • Dr. Edward M. Kaye M.D.Dr. Edward M. Kaye M.D. (Age 73)
    Ph.D., CEO & Director
    Comp: $938.37k
  • Dr. Adrian R. Krainer Ph.D. (Age 63)
    Co-Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $89k
  • Mr. Stephen J. Tulipano CPA (Age 63)
    CPA, MBA, Chief Financial Officer
    Comp: $617.07k
  • Dr. Barry S. Ticho FACC (Age 61)
    M.D., Ph.D., Chief Medical Officer
    Comp: $664.99k
  • Ms. Isabel Aznarez Ph.D. (Age 49)
    Co-Founder & Group VP of Discovery Research
  • Dr. Huw M. Nash Ph.D. (Age 55)
    COO & Chief Bus. Officer
  • Mr. Jonathan Allan J.D.
    Gen. Counsel
  • Ms. Dawn Kalmar (Age 44)
    Chief Communications Officer
  • Ms. Joan Wood
    Chief HR Officer
  • Ms. Shamim Ruff (Age 62)
    Chief Regulatory Officer













STOK Stock - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price forecast for 2022?

5 analysts have issued 1-year price targets for Stoke Therapeutics' shares. Their STOK share price forecasts range from $38.00 to $50.00. On average, they expect the company's share price to reach $44.83 in the next year. This suggests a possible upside of 244.1% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2022?

Stoke Therapeutics' stock was trading at $23.99 on January 1st, 2022. Since then, STOK shares have decreased by 45.7% and is now trading at $13.03.
View the best growth stocks for 2022 here
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its quarterly earnings results on Monday, August, 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.07. The firm had revenue of $3.23 million for the quarter, compared to analysts' expectations of $2.71 million.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (7.52%), Cowen AND Company LLC (3.86%), Bank of Montreal Can (2.57%), Millennium Management LLC (2.41%), Healthcare of Ontario Pension Plan Trust Fund (2.31%) and Deutsche Bank AG (2.00%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker, Rtw Investments, Lp and Stephen J Tulipano.
View institutional ownership trends
.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $13.03.

How much money does Stoke Therapeutics make?

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $513.64 million. The company earns $-85,810,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

The company employs 102 workers across the globe.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.

This page (NASDAQ:STOK) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.